Anagramas & Información sobre | Palabra Inglés PNH

Ejemplos de uso de PNH en una oración

• They are usually associated with multiple sclerosis or pertussis, but they may also be observed in other disorders such as encephalitis, head trauma, stroke, autism, asthma, trigeminal neuralgia, breath-holding spells, epilepsy, malaria, tabes dorsalis, and Behçet's disease, paroxysmal nocturnal hemoglobinuria (PNH).
• Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood characterized by destruction of red blood cells by the complement system, a part of the body's innate immune system.
• As the PLH were unable to decide on a single candidate they ended up fielding four candidates, including Azcona, against the one National Party of Honduras (PNH) candidate Rafael Leonardo Callejas Romero.
• His election, for the National Party of Honduras (PNH), ended the 16-year dictatorship of Tiburcio Carías Andino.
• Diseases with excessive complement activation include paroxysmal nocturnal hemoglobinuria (PNH), and inhibitors of Factor D may have utility in the treatment of PNH.
• Because DAF is a GPI-anchored protein, its expression is reduced in persons with mutations that reduce GPI levels such as those with paroxysmal nocturnal hemoglobinuria (PNH).
• Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq), used to treat hypophosphatasia; sebelipase alfa (Kanuma), used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa), used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.
• Fluorescein-labeled proaerolysin (FLAER) is used in a flow cytometric assay to diagnose paroxysmal nocturnal hemoglobinuria (PNH).
• Patient red blood cells (RBCs) are placed in mild acid; a positive result (increased RBC fragility) indicates PNH or congenital dyserythropoietic anemia.
• Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome.
• The assay was developed as an extension of flow cytometric procedure for diagnosing human acquired genetic disorder, paroxysmal nocturnal hemoglobinuria (PNH).
• Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH).
• Iptacopan, sold under the brand name Fabhalta, is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
• In October 2024, the National Institute for Health and Care Excellence (NICE) adopted a recommendation for danicopan as an add-on therapy for adults with the paroxysmal nocturnal haemoglobinuria (PNH) based results from the phase 3 ALPHA trial, which evaluated the efficacy and safety of the drug as an add-on to ravulizumab or eculizumab in patients with PNH who experienced clinically significant extravascular haemolysis.

La preparación de la página tomó: 329,88 ms.